FY2025 · ended Dec 31, 2025 · Revenue $12.29M, -15.0% YoY · Filed Mar 13, 2026
Elutia Inc. (ELUT) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $12.3 million and net income of $53.4 million. Free cash flow was -$46.7 million. As of Jun 30, 2026 it held $19.9 million in cash and investments and $3.7 million in total debt.
Revenue (TTM)
$12.14M
+69.0% vs year-ago TTM
Net income (TTM)
$51.81M
+343.0% vs year-ago TTM
Operating cash flow (TTM)
$-43.99M
-34.2% vs year-ago TTM
Free cash flow (TTM)
$-46.03M
-36.1% vs year-ago TTM
EPS (TTM)
$1.14
+37.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
648,277
Net cash
$16.20M
as of Jun 30, 2026
Operating margin
-214.8%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ELUT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Silver Spring, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1708527
- Former names
- AZIYO BIOLOGICS, INC. (until Aug 14, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $12.3M | $14.5M | $24.7M | $23.8M | $47.4M |
| Operating income | -$26.9M | -$30.7M | -$30.5M | -$35.2M | -$23.0M |
| Net income | $53.4M | -$53.9M | -$37.7M | -$32.9M | -$24.8M |
| Diluted EPS | $0.87 | -$1.86 | -$2.07 | -$2.38 | -$2.38 |
| Operating cash flow | -$44.8M | -$22.7M | -$21.8M | -$21.4M | -$15.4M |
| Free cash flow | -$46.7M | -$23.3M | -$22.1M | -$22.0M | -$15.8M |
| Total assets | $62.4M | $36.1M | $43.4M | $68.8M | $67.2M |
| Total liabilities | $34.7M | $82.4M | $82.0M | $73.9M | $53.6M |
| Stockholders' equity | $27.7M | -$46.3M | -$38.6M | -$5.0M | $13.5M |
| Cash and investments | $36.4M | $13.2M | $19.3M | $17.0M | $30.4M |
| Total debt | $3.9M | $24.0M | $24.0M | $24.5M | $26.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Acquisition or sale of assets, Regulation FD disclosure
|
Aug 21, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 7, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 20, 2026 | Jul 16, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 16, 2026 | Jun 11, 2026 |
All 369 Elutia Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.